Media & Announcements
Polpharma Group at CPHI Milan 2026: Strengthening Partnerships Across the Global Pharmaceutical Value Chain
At CPHI Milan 2026, a Polpharma delegation led by CEO Sebastian Szymanek met partners on APIs, finished dosage forms, CDMO services and new technologies.
Group News
October 21, 2026
Polpharma at EFNI 2026: Building Innovation, Resilience and Europe’s Future
At EFNI 2026 in Sopot, Polpharma shared its innovation experience and joined debates on resilient supply chains and Europe’s industrial future.
Group News
October 21, 2026
Polpharma strengthens it's position in CEE - Biofarm, the leader of the Romanian market, joins the Group.
Polpharma Group has completed the acquisition of the Romanian pharmaceutical company Biofarm. The transaction is a clear step in the execution of the Group’s growth strategy and strengthens its position in Central and Eastern Europe.
Group News
July 27, 2026
Polpharma Group’s R&D supports growth in key therapeutic areas.
Polpharma Group's research and development capabilities support growth across its key therapeutic areas and strengthen its product pipeline.
Group News
June 26, 2026
Polpharma strengthens it's position in CEE - Biofarm, the leader of the Romanian market, joins the Group.
Polpharma Group has completed the acquisition of the Romanian pharmaceutical company Biofarm. The transaction is a clear step in the execution of the Group’s growth strategy and strengthens its position in Central and Eastern Europe.
Group News
July 27, 2026
.avif)
.avif)
The Leonardo Innovation Program won the Gold Stevie Awards® gold statuette in the 19th edition of the prestigious international competition International Business Awards®!
The Leonardo employee innovation programme wins Gold at the Stevie International Business Awards for creativity, engagement and innovative communication.
Group News
August 16, 2022
Polpharma API completed step 1. Risk Evaluation according to EMA’s request concerning presence of nitrosamines in drug products.
Polpharma completed EMA risk assessment for nitrosamines in chemically synthesised APIs, identifying optimisation parameters for highest quality.
Group News
December 17, 2020
Press releases
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Careers
ZF Polpharma
March 4, 2021
Polpharma at the top in the category of the exact sciences in the study „Most Attractive Employer Poland” 2020
Polpharma tops the Natural Sciences category in Universum's Most Attractive Employer Poland 2020 study, voted by over 16,000 students from 71 universities.
Corporate Social Responsibility
ZF Polpharma
February 10, 2021
Polpharma’s Office Certified as a “Building without Barriers”
Polpharma's modernised office receives the Building without Barriers certificate, confirming accessibility for people with disabilities after an expert audit.
Corporate Social Responsibility
Polpharma Group
January 18, 2021
Polpharma joins the Climate Leadership programme
Polpharma joins the Climate Leadership programme run by UNEP/GRID-Warsaw, committing to clean energy, lower greenhouse gas emissions and climate neutrality.
Science & Innovation
ZF Polpharma
December 21, 2020
The first Polish test to distinguish between COVID-19 and flu to be placed on the market
The MediPAN-COVID+Flu genetic test, developed by PAS scientists with Polpharma and partners, detects SARS-CoV-2 and influenza A and B in a single reaction.
Group News
Polpharma API
December 17, 2020
Polpharma API completed step 1. Risk Evaluation according to EMA’s request concerning presence of nitrosamines in drug products.
Polpharma completed EMA risk assessment for nitrosamines in chemically synthesised APIs, identifying optimisation parameters for highest quality.
Latest stories
featured
.avif)
For the media
Media Kit
Logos, photography and the Group boilerplate.
ZIP file (112.28 kb) updated quarterly
Group factsheet
Revenue, footprint, pipeline, employment and history.
Pdf file (112.28 kb) updated quarterly
Press Contact
Logos, photography and the Group boilerplate.
press@polpharma.com
RESPONDS WITHIN ONE BUSINESS DAY